Transcervical Fibroid Ablation (TFA): Current Status and New Developments

Aim Transcervical fibroid ablation offers a non-invasive alternative to traditional surgical options for the treatment of symptomatic uterine fibroids using real-time visualization using intrauterine ultrasound guidance. Purpose of Review To review the recent clinical literature on transcervical fib...

Full description

Saved in:
Bibliographic Details
Published inCurrent obstetrics and gynecology reports Vol. 13; no. 4; pp. 237 - 245
Main Authors Roy, K. H., Lindner, Leslie Hansen, Gill, Tasha L., Hurst, Bradley S.
Format Journal Article
LanguageEnglish
Published New York Springer US 09.10.2024
Subjects
Maternal and Child Health
Medicine
Medicine & Public Health
Obstetrics/Perinatology/Midwifery
Oncology
Review
Topical Collection on Emerging and Pipeline Technologies in Ob/Gyn
Transcervical fibroid ablation
Radiofrequency ablation
Uterine myoma
Fibroids
Intrauterine sonography
Sonata
Online AccessGet full text

Cover

More Information
Summary:Aim Transcervical fibroid ablation offers a non-invasive alternative to traditional surgical options for the treatment of symptomatic uterine fibroids using real-time visualization using intrauterine ultrasound guidance. Purpose of Review To review the recent clinical literature on transcervical fibroid ablation (TFA) with the Sonata ® System and discuss new developments in the use of such technology. Recent Findings Nearly six years since the Food and Drug Administration (FDA) approval in the United States (2018) and 14 years since receiving CE Mark in Europe, TFA with the Sonata system has been used to treat over 30,000 myomas in more than 10,000 procedures world-wide. Data regarding pregnancy outcomes, timing of pregnancy, route of delivery, neoadjuvant use of GnRH analogues and whether TFA is an effective treatment for adenomyosis remain fertile areas for investigation. Significant complications have been rarely reported. Summary TFA continues to be an increasingly adopted treatment modality that can safely address symptomatic uterine fibroids in a transcervical fashion. TFA provides a uterus-sparing, durable treatment associated with quick recovery, low re-intervention rates and high patient satisfaction. Preliminary findings support the use of TFA for additional treatment considerations, including adenomyosis and pregnancy outcomes. However, further research is needed to establish its efficacy and safety in these areas.
ISSN:2161-3303
2161-3303
DOI:10.1007/s13669-024-00403-z